Back to News
Market Impact: 0.12
Inomagen Therapeutics, Inc. Awarded NIH SBIR Grant Providing up to $2.9 million to Advance Disease-Modifying Gene Therapy for Atrial Fibrillation
Source: PRWeb
Healthcare & BiotechTechnology & Innovation
Inomagen Therapeutics received an award to fund key preclinical and manufacturing activities for its non-viral gene-therapy program. The funding is intended to advance the program toward a future Investigational New Drug application, representing an early-stage development milestone with limited near-term market impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.28
More News
- US official says upcoming spectrum auctions could generate more than $100 billion
- Investors react to Fed hike and market sell-off: Brace for 'higher for longer' rates
- AI Buildout Hits Inflation as Fed Hikes Rates
- OpenAI discloses six more instances of ’concerning’ AI model behavior
- The Competition's Response to Tesla Robotaxi Day
- Snap tries to bring AR glasses to enterprise market, partnering with Nvidia, AWS and Salesforce
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Best AI Stock Research Tools for Professional Investors
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More